Experience of measles-mumps-rubella vaccine among children with egg allergy

<p><strong><span>Objective: </span></strong><span>Patients with egg allergy have had hesitations about </span><span>measles-mumps-rubella</span><strong><span> (</span></strong><span>MMR) vaccination for a long time due to the egg protein contained in the vaccine. In this study, we aimed to share our clinical experience on this subject.</span></p>\n<p><strong><span>Methods: </span></strong><span>This descriptive study included all 179 patients with egg </span><span>allergies who</span><span> received MMR in our clinic between 2015</span><span> and </span><span>2022. The patients’ age, </span><span>sex</span><span>, clinical findings, allergy tests, total IgE, eosinophil values, </span><span>and postvaccine</span><span> reaction status were evaluated retrospectively.</span></p>\n<p><strong><span>Results: </span></strong><span>The median age of those vaccinated in our clinic </span><span>was</span><span> 13.0 months (9.0-84.0). The median value for the calendar delay in the vaccine dose was 1.0 months (minimum: 0, maximum: 72.0). The median absolute eosinophil value of the patients was 360.0 10<sup>3</sup>/uL (10.0-2220.0), the median eosinophil value (%) was 3.4% (0.1-20.0%), and the median total IgE value was 53.5 IU/mL (1.0-2500.0). The most common clinical findings were atopic dermatitis and urticaria (54.7% and 44.1%, respectively). No patient had developed a previous anaphylaxis. A </span><span>postvaccine</span><span> reaction developed in one out of 179 children who received </span><span>the </span><span>MMR vaccine. This patient presented with urticaria. No serious reaction was observed in any of the other patients.</span></p>\n<p><strong><span>Conclusion: </span></strong><span>Children with egg allergy should be evaluated by </span><span>pediatric</span><span> allergy clinics; however, this should not cause a delay in the MMR vaccination schedule.</span></p>